426 related articles for article (PubMed ID: 18256372)
1. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.
Alon US; Levy-Olomucki R; Moore WV; Stubbs J; Liu S; Quarles LD
Clin J Am Soc Nephrol; 2008 May; 3(3):658-64. PubMed ID: 18256372
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review.
Yavropoulou MP; Kotsa K; Gotzamani Psarrakou A; Papazisi A; Tranga T; Ventis S; Yovos JG
Hormones (Athens); 2010; 9(3):274-8. PubMed ID: 20688626
[TBL] [Abstract][Full Text] [Related]
3. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet.
Raeder H; Shaw N; Netelenbos C; Bjerknes R
Eur J Endocrinol; 2008 Dec; 159 Suppl 1():S101-5. PubMed ID: 18775977
[TBL] [Abstract][Full Text] [Related]
4. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.
Carpenter TO; Insogna KL; Zhang JH; Ellis B; Nieman S; Simpson C; Olear E; Gundberg CM
J Clin Endocrinol Metab; 2010 Nov; 95(11):E352-7. PubMed ID: 20685863
[TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet in the management of tumor-induced osteomalacia.
Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
[TBL] [Abstract][Full Text] [Related]
8. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.
Lee YT; Ng HY; Kuo CC; Chen TC; Wu CS; Chiu TT; Lee WC; Lee CT
Nutrients; 2013 Apr; 5(4):1336-48. PubMed ID: 23603995
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.
Carpenter TO; Imel EA; Ruppe MD; Weber TJ; Klausner MA; Wooddell MM; Kawakami T; Ito T; Zhang X; Humphrey J; Insogna KL; Peacock M
J Clin Invest; 2014 Apr; 124(4):1587-97. PubMed ID: 24569459
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
[TBL] [Abstract][Full Text] [Related]
11. Effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on tubular handling of phosphate in hypophosphatemic rickets.
Alon U; Chan JC
J Clin Endocrinol Metab; 1984 Apr; 58(4):671-5. PubMed ID: 6546575
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
Kuczera P; Adamczak M; Wiecek A
Clin Endocrinol (Oxf); 2014 Apr; 80(4):607-12. PubMed ID: 24111496
[TBL] [Abstract][Full Text] [Related]
13. Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?
Lomonte C; Vernaglione L; Chimienti D; Bruno A; Cocola S; Teutonico A; Cazzato F; Basile C
Clin J Am Soc Nephrol; 2008 May; 3(3):794-9. PubMed ID: 18322048
[TBL] [Abstract][Full Text] [Related]
14. 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.
Liu ES; Martins JS; Raimann A; Chae BT; Brooks DJ; Jorgetti V; Bouxsein ML; Demay MB
J Bone Miner Res; 2016 May; 31(5):929-39. PubMed ID: 26751835
[TBL] [Abstract][Full Text] [Related]
15. Effects of cinacalcet in renal transplant patients with hyperparathyroidism.
Courbebaisse M; Diet C; Timsit MO; Mamzer MF; Thervet E; Noel LH; Legendre C; Friedlander G; Martinez F; Prié D
Am J Nephrol; 2012; 35(4):341-8. PubMed ID: 22473131
[TBL] [Abstract][Full Text] [Related]
16. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.
Wetmore JB; Liu S; Krebill R; Menard R; Quarles LD
Clin J Am Soc Nephrol; 2010 Jan; 5(1):110-6. PubMed ID: 19965548
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
Chertow GM; Blumenthal S; Turner S; Roppolo M; Stern L; Chi EM; Reed J;
Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
[TBL] [Abstract][Full Text] [Related]
18. FGF23 and Associated Disorders of Phosphate Wasting.
Gohil A; Imel EA
Pediatr Endocrinol Rev; 2019 Sep; 17(1):17-34. PubMed ID: 31599133
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
[TBL] [Abstract][Full Text] [Related]
20. Effect of dipyridamole on serum and urinary phosphate in X-linked hypophosphatemia.
Seikaly MG; Quigley R; Baum M
Pediatr Nephrol; 2000 Nov; 15(1-2):57-9. PubMed ID: 11095012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
